Drug intelligence / Profile preview

zuberitamab (Beijing Tianguangshi Pharmaceutical Technology)

Development stage: Unknown
Lead developer: BioRay
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Zuberitamab (MIL62) is a glycoengineered, humanized Type II anti-CD20 monoclonal antibody developed by Beijing Mabworks Biotech. It is designed to target the CD20 antigen on the surface of B-cells with enhanced antibody-dependent cellular cytotoxicity (ADCC) and potent pro-apoptotic activity compared to first-generation anti-CD20 antibodies like rituximab. By utilizing a fucose-deficient glycoengineering approach, zuberitamab exhibits increased affinity for the FcγRIIIa receptor on effector cells, thereby augmenting its immune-mediated cell-killing capabilities. Zuberitamab is currently being evaluated in clinical trials for various B-cell malignancies, including mantle cell lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma, as well as autoimmune conditions such as primary membranous nephropathy.

Other names: Zuberitamb朱伯利单抗

Targets

CD20 (B-lymphocyte antigen CD20)

Beyond the preview

Go deeper on zuberitamab (Beijing Tianguangshi Pharmaceutical Technology).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zuberitamab (Beijing Tianguangshi Pharmaceutical Technology).

Explore the full profile